Oxbryta (voxelotor): Withdrawal from UK market
Pfizer Limited in agreement with the Medicines and Healthcare products Regulatory Agency (MHRA) need to inform you that Oxbryta (voxelotor) is being withdrawn from the UK market while a review...
Read MoreBREAKING NEWS: UKTS launches the 4th Edition (2023) of their Standards
BREAKING NEWS: UKTS launches the 4th Edition (2023) of their “Standards for the Clinical Care of Treatment of Children and Adult’s living with Thalassaemia in the United Kingdom” Read the...
Read MoreExagamglogene autotemcel for treating sickle cell disease [ID4016] – Extra Documents
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE - Extra Single Technology Appraisal Exagamglogene autotemcel for treating sickle cell disease Dear stakeholders, 2 additional documents have been added to the technical engagement...
Read MoreExagamglogene autotemcel for treating sickle cell disease [ID4016] – update
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE - Single Technology Appraisal Single Technology Appraisal Exagamglogene autotemcel for treating sickle cell disease Dear stakeholders, After very careful consideration, we have taken...
Read MoreExagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015] – Update
Appraisal of exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia Dear registrant NICE has taken the decision to postpone the first appraisal committee meeting for this topic. The committee discussion planned...
Read More
NHS Offers Allo Haematopoietic Stem Cell Transplant for Adults with Transfusion Dependent Thalassaemia
BREAKING NEWS: NHS Offers Allo Haematopoietic Stem Cell Transplant (Allo-HSCT) for Adults with Transfusion Dependent Thalassaemia (TDT) Read the full article
Read MoreProgression Decision Point Outcome Exagamglogene autotemcel for treating sickle cell disease [ID4016]
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE - Progression Decision Point Outcome Exagamglogene autotemcel for treating sickle cell disease Registration & more information
Read MoreExagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE - Technology Appraisal Committee Meeting Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia Registration & more information
Read MorePreparations for blood group genotyping for people with sickle cell, thalassemia and rare anaemia
The NHS in England will soon be able to offer blood group and HLA genotyping for the current cohort of people with sickle cell, thalassaemia and transfusion dependent rare anaemias,...
Read MoreEducational resources for men experiencing SCD and an associated condition called priapism
Educational resources for men experiencing sickle cell disorder and an associated condition called priapism which have been published today and we thought would be of interest to your members and...
Read MoreSickle cell digital discovery report -Designing better acute painful sickle cell care
Today we have published a new report ‘Sickle cell digital discovery report - Designing better acute painful sickle cell care’. This study set out to fully understand the broad availability...
Read MoreHaemoglobinopathy Peer review for Children and Adults
Dear Red Cell Colleagues, I am delighted to let you know that the next round of Haemoglobinopathy Peer review for Children and Adults is going to be starting next year....
Read MoreLetter to NHP re blood stocks – 121022
The National Blood Transfusion service has sent out an Amber Alert on stock levels. Direct communications have been made to all NHS Trusts who will be enacting local responses and...
Read MoreApply to be a Committee Members.
Interested parties should submit a short (max 200 word) summary of their area of interest and how they can add to the existing membership. Submissions may be sent directly to...
Read More
Emma trained at St Barts and the Royal London School of Medicine, University of London and qualified in 2001 and is currently working as a Haematology Consultant between UCLH and the Whittington Hospital. She was Clinical Lecturer in Sickle Cell Disease at King’s College Hospital from 2009 to 2013 and during that time was awarded her PhD based on research into markers of severity and predictors of organ dysfunction in sickle cell disease. In 2013 she was awarded the Early Stage Investigator prize from the British Society of Haematology. She is the Haemoglobinopathy Coordinating Centre lead for North Central and West London, East Anglia and the South West and Central England.
Dr Subarna Chakravorty is a Paediatric Haematologist with a special interest in non-malignant haematology and stem cell transplant for haemoglobinopathy and non-malignant diseases. She joined King’s College Hospital as consultant in July 2015. Prior to that, Subarna led the Paediatric Haemoglobinopathy service at Imperial College Healthcare NHS Trust and the Imperial Paediatric Red Cell Disorders Network for 5 years, where she was also involved in the bone marrow transplant programme for paediatric haemoglobinopathy. Since 2021, Subarna has been involved in the adult sickle cell bone marrow transplant service at King’s College Hospital.
Dr Rachel Kesse-Adu is a consultant haematologist who qualified in medicine from Imperial College School of Medicine in 2002 and completed her specialist training in haematology at Kings College Hospital in London in 2012. 
John James OBE has 33 years of experience within the NHS including 4 CEO roles. He was Chair of the West London Cancer network (2002-2005) and Chair of the North West London Diabetes Network (2003-2004). 